Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	48.89	52.89	76.33	109.11	112.58	85.21
Short-Term Investments	-	-	-	-	33.82	41.7
Cash & Short-Term Investments	48.89	52.89	76.33	109.11	146.4	126.91
Cash Growth	-40.58%	-30.71%	-30.04%	-25.47%	15.36%	54.68%
Accounts Receivable	23.61	49.39	49.15	-	-	-
Other Receivables	0.67	3.09	1.55	1.08	2.64	6.18
Receivables	24.28	52.48	50.7	1.08	2.64	6.18
Prepaid Expenses	1.55	1.91	4.18	3.38	8.83	6.06
Total Current Assets	74.71	107.28	131.21	113.57	157.87	139.15
Property, Plant & Equipment	2.84	3.11	4.16	5.49	7.56	8.78
Long-Term Accounts Receivable	-	-	46.59	-	-	-
Other Long-Term Assets	0.15	0.15	0.44	5.74	5.64	5.52
Total Assets	77.71	110.54	182.39	124.8	171.07	153.45
Accounts Payable	1.77	7.31	1.38	0.62	1.1	1.16
Accrued Expenses	8.05	17.27	6.56	8.53	14.35	12.24
Current Portion of Leases	1.8	1.75	1.72	1.69	1.36	0.95
Current Income Taxes Payable	0.17	0.17	0.39	-	-	-
Current Unearned Revenue	17.23	22.12	27.11	10.37	1.86	-
Other Current Liabilities	0.14	0.46	-	0.45	-	-
Total Current Liabilities	29.16	49.07	37.15	21.65	18.67	14.34
Long-Term Debt	-	-	-	-	48.41	-
Long-Term Leases	2.17	2.55	3.83	4.96	5.97	6.89
Long-Term Unearned Revenue	12.58	12.8	34.43	22.17	8.79	-
Other Long-Term Liabilities	-	-	0.09	0.1	0.94	0.18
Total Liabilities	43.9	64.42	75.5	48.87	82.78	21.41
Common Stock	0.06	0.06	0.05	0.05	0.03	0.03
Additional Paid-In Capital	507.26	505.71	497.91	489.76	455.72	409.72
Retained Earnings	-473.5	-459.64	-391.07	-413.88	-367.46	-277.71
Comprehensive Income & Other	-	-	-	-	-0	-0.01
Total Common Equity	33.81	46.12	106.89	75.93	88.29	132.04
Shareholders' Equity	33.81	46.12	106.89	75.93	88.29	132.04
Total Liabilities & Equity	77.71	110.54	182.39	124.8	171.07	153.45
Total Debt	3.96	4.3	5.54	6.65	55.75	7.84
Net Cash (Debt)	44.93	48.59	70.79	102.46	90.65	119.07
Net Cash Growth	-41.67%	-31.36%	-30.91%	13.02%	-23.86%	55.64%
Net Cash Per Share	0.82	0.90	1.34	2.73	2.93	5.32
Filing Date Shares Outstanding	55.91	55.9	53.87	52.57	32.76	29.5
Total Common Shares Outstanding	55.9	54.59	53	52.46	32.39	29.26
Working Capital	45.56	58.2	94.06	91.92	139.2	124.8
Book Value Per Share	0.60	0.84	2.02	1.45	2.73	4.51
Tangible Book Value	33.81	46.12	106.89	75.93	88.29	132.04
Tangible Book Value Per Share	0.60	0.84	2.02	1.45	2.73	4.51
Machinery	-	1.55	1.55	1.55	1.76	1.76
Construction In Progress	-	-	-	-	-	0.04
Leasehold Improvements	-	1.64	1.64	1.64	1.64	1.64

Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q